<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0807245504
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CEBO 200 MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CELECOXIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Atlantic Pharma " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Atlantic Pharma 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AH01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">CEBO contains the active substance celecoxib.</p><p style="text-align:justify">CEBO is used for the relief of signs and symptoms of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis.</p><p style="text-align:justify">CEBO belongs to a group of medicinal products called nonsteroidal anti-inflammatory drugs (NSAID), and specifically a sub-group known as (COX-2) inhibitors. Your body makes prostaglandins that may cause pain and inflammation. In conditions such as rheumatoid arthritis and osteoarthritis your body makes more of these. CEBO acts by reducing the production of prostaglandins, thereby reducing the pain and inflammation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">You have been prescribed CEBO by your doctor. The following information will help you get the best results with CEBO. If you have any further questions please ask your doctor or pharmacist.</p><p style="text-align:justify"><strong>Do not take CEBO</strong><br />Tell your doctor if any of the following are true for you as patients with these conditions should not take CEBO.</p><ul><li style="text-align:justify">if you are allergic to celecoxib or any of the other ingredients of this medicine (listed in section 6)</li><li style="text-align:justify">if you have had an allergic reaction to a group of medicines called &ldquo;sulphonamides&rdquo; (e.g. some antibiotics used to treat infections)</li><li style="text-align:justify">if you currently have an ulcer in your stomach or intestines, or bleeding in your stomach or intestines</li><li style="text-align:justify">if as a result of taking acetylsalicylic acid or any other anti-inflammatory and pain-relieving medicine (NSAID) you have had asthma, nose polyps, severe nose congestion, or an allergic reaction such as an itchy skin rash, swelling of the face, lips, tongue or throat, breathing difficulties or wheezing</li><li style="text-align:justify">if you are pregnant. If you can become pregnant during ongoing treatment you should discuss methods of contraception with your doctor</li><li style="text-align:justify">if you are breast-feeding</li><li style="text-align:justify">if you have severe liver disease</li><li style="text-align:justify">if you have severe kidney disease</li><li style="text-align:justify">if you have an inflammatory disease of the intestines such as ulcerative colitis or Crohn&rsquo;s disease</li><li style="text-align:justify">if you have heart failure, established ischaemic heart disease, or cerebrovascular disease, e.g. you have been diagnosed with a heart attack, stroke, or transient ischaemic attack (temporary reduction of blood flow to the brain; also known as &ldquo;mini-stroke&rdquo;), angina, or blockages of blood vessels to the heart or brain</li><li style="text-align:justify">if you have or have had problems with your blood circulation (peripheral arterial disease) or if you have had surgery on the arteries of your legs</li></ul><p style="text-align:justify"><strong>Warnings and precautions</strong><br />Talk to your doctor, pharmacist or nurse before taking CEBO</p><ul><li style="text-align:justify">if you have previously had an ulcer or bleeding in your stomach or intestines. (Do not take CEBO if you currently have an ulcer or bleeding in your stomach or intestine).</li><li style="text-align:justify">if you are taking acetylsalicylic acid (even at low dose for heart protective purposes)</li><li style="text-align:justify">if you use medicines to reduce blood clotting (e.g. warfarin)</li><li style="text-align:justify">if you are using CEBO at the same time as other non-acetylsalicylic NSAIDs such as ibuprofen or diclofenac. The use of these medicines together should be avoided</li><li style="text-align:justify">if you smoke, have diabetes, raised blood pressure or raised cholesterol</li><li style="text-align:justify">-f your heart, liver or kidneys are not working well your doctor may want to keep a regular check on you</li><li style="text-align:justify">If you have fluid retention (such as swollen ankles and feet)</li><li style="text-align:justify">if you are dehydrated, for instance due to sickness, diarrhoea or the use of diuretics (used to treat excess fluid in the body)</li><li style="text-align:justify">if you have had a serious allergic reaction or a serious skin reaction to any medicines</li><li style="text-align:justify">if you feel ill due to an infection or think you have an infection, as CEBO may mask a fever or other signs of infection and inflammation</li><li style="text-align:justify">if you are over 65 years of age your doctor may want to keep a regular check on you</li></ul><p style="text-align:justify">As with other NSAIDs (e.g. ibuprofen or diclofenac) this medicine may lead to an increase in blood pressure, and so your doctor may ask to monitor your blood pressure on a regular basis.</p><p style="text-align:justify">Some cases of severe liver reactions, including severe liver inflammation, liver damage, liver failure (some with fatal outcome or requiring liver transplant), have been reported with celecoxib. Of the cases that reported time to onset, most severe liver reactions occurred within one month of start of treatment.</p><p style="text-align:justify">CEBO may make it more difficult to become pregnant. You should inform your doctor if you are planning to become pregnant or if you have problems to become pregnant (see section on Pregnancy and breast-feeding).</p><p style="text-align:justify"><strong>Other medicines and CEBO</strong><br />Some medicines can affect the way other medicines work.</p><p style="text-align:justify">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines:</p><ul><li style="text-align:justify">Dextromethorphan (used to treat coughs)</li><li style="text-align:justify">ACE inhibitors or angiotensin II antagonists (used for high blood pressure and heart failure)</li><li style="text-align:justify">Diuretics (used to treat excess fluid in the body)</li><li style="text-align:justify">Fluconazole and rifampicin (used to treat fungal and bacterial infections)</li><li style="text-align:justify">Warfarin or other oral anticoagulants (&ldquo;blood-thinning&rdquo; agents that reduce blood clotting)</li><li style="text-align:justify">Lithium (used to treat some types of depression)</li><li style="text-align:justify">Other medicines to treat depression, sleep disorders, high blood pressure or an irregular heartbeat</li><li style="text-align:justify">Neuroleptics (used to treat some mental disorders)</li><li style="text-align:justify">Methotrexate (used to treat rheumatoid arthritis, psoriasis and leukaemia)</li><li style="text-align:justify">Carbamazepine (used to treat epilepsy/seizures and some forms of pain or depression)</li><li style="text-align:justify">Barbiturates (used to treat epilepsy/seizures and some sleep disorders)</li><li style="text-align:justify">Ciclosporin and tacrolimus (used for immune system suppression e.g. after transplants)</li></ul><p style="text-align:justify">CEBO can be taken with low dose acetylsalicylic acid (75mg or less daily). Ask your doctor for advice before taking both medicines together.</p><p style="text-align:justify"><strong>Pregnancy, breast-feeding and fertility</strong><br />CEBO must not be used by women who are pregnant or can become pregnant (i.e. women of child bearing potential who are not using adequate contraception) during ongoing treatment. If you become pregnant during treatment with CEBO you should discontinue the treatment and contact your doctor for alternative treatment.</p><p style="text-align:justify">CEBO must not be used during breast-feeding.</p><p style="text-align:justify">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p style="text-align:justify"><strong>Driving and using machines</strong><br />You should be aware of how you react to CEBO before you drive or operate machinery. If you feel dizzy or drowsy after taking CEBO, do not drive or operate machinery until these effects wear off.</p><p style="text-align:justify"><strong>CEBO contains lactose (a type of sugar)</strong><br />If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. If you think or feel that the effect of CEBO is too strong or too weak, talk to your doctor or pharmacist.</p><p style="text-align:justify">Your doctor will tell you what dose you should take. As the risk of side effects associated with heart problems may increase with dose and duration of use, it is important that you use the lowest dose that controls your pain and you should not take CEBO for longer than necessary to control symptoms.</p><p style="text-align:justify">CEBO should be swallowed whole with a drink of water. The capsules can be taken at any time of the day, with or without food. However, try to take each dose of CEBO at the same time each day.</p><p style="text-align:justify">Contact your doctor within two weeks of starting treatment if you do not experience any benefit.</p><p style="text-align:justify"><strong>Dosage</strong></p><p style="text-align:justify"><u>200 mg capsule, hard:</u><br /><em>For osteoarthritis</em><br />the recommended daily dose is 200 mg (1 capsule, hard once a day), increased by your doctor to a maximum of 400 mg (1 capsule, hard twice a day), if needed.</p><p style="text-align:justify"><em>For rheumatoid arthritis</em><br />the initial recommended daily dose is 200 mg (as one 100 mg capsule, hard twice a day), increased by your doctor to a maximum of 400 mg (1 capsule, hard twice a day), if needed.</p><p style="text-align:justify"><em>For ankylosing spondylitis</em><br />the recommended daily dose is 200 mg (1 capsule, hard once a day), increased by your doctor to a maximum of 400 mg (2 capsules, hard once a day or 1 capsule, hard twice a day), if needed.</p><p style="text-align:justify"><em>Kidney or liver problems</em>: make sure your doctor knows if you have liver or kidney problems as you may need a lower dose.</p><p style="text-align:justify"><em>The elderly, especially those with a weight less than 50 kg:</em> if you are over 65 years of age and especially if you weigh less than 50 kg, your doctor may want to monitor you more closely.</p><p style="text-align:justify"><em>Use in children:</em> CEBO is for adults only, it is not for use in children.</p><p style="text-align:justify"><strong>You should not take more than 400 mg per day.</strong></p><p style="text-align:justify"><strong>If you take more CEBO than you should</strong><br />You should not take more capsules than your doctor tells you to. If you take too many capsules contact your doctor, pharmacist or hospital and take your medicine with you.</p><p style="text-align:justify"><strong>If you forget to take CEBO</strong><br />If you forget to take a capsule, take it as soon as you remember. Do not take a double dose to make up for forgotten doses.</p><p style="text-align:justify"><strong>If you stop taking CEBO</strong><br />Suddenly stopping your treatment with CEBO may lead to your symptoms getting worse. Do not stop taking CEBO unless your doctor tells you to. Your doctor may tell you to reduce the dose over a few days before stopping completely.</p><p style="text-align:justify">If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p style="text-align:justify">The side effects listed below were observed in arthritis patients who took celecoxib. Side effects marked with an asterisk (*) are listed below at the higher frequencies that occurred in patients who took celecoxib to prevent colon polyps. Patients in these studies took celecoxib at high doses and for a long duration.</p><p style="text-align:justify">If any of the following happen, stop taking CEBO and tell your doctor immediately:<br />If you have:</p><ul><li style="text-align:justify">an allergic reaction such as skin rash, swelling of the face, wheezing or difficulty breathing</li><li style="text-align:justify">heart problems such as pain in the chest</li><li style="text-align:justify">severe stomach pain or any sign of bleeding in the stomach or intestines, such as passing black or bloodstained stools, or vomiting blood.</li><li style="text-align:justify">a skin reaction such as rash, blistering or peeling of the skin</li><li style="text-align:justify">liver failure (symptoms may include nausea (feeling sick), diarrhoea, jaundice (your skin or the whites of your eyes look yellow)).</li></ul><p style="text-align:justify"><strong>Very common: may affect more than 1 in 10 people</strong></p><ul><li style="text-align:justify">High blood pressure*</li></ul><p style="text-align:justify"><strong>Common: may affect up to 1 in 10 people</strong></p><ul><li style="text-align:justify">Heart attack*</li><li style="text-align:justify">Fluid build up with swollen ankles, legs and/or hands</li><li style="text-align:justify">Urinary infections</li><li style="text-align:justify">Shortness of breath*, sinusitis (sinus inflammation, sinus infection, blocked or painful sinuses), blocked or runny nose, sore throat, coughs, colds, flu-like symptoms</li><li style="text-align:justify">Dizziness, difficulty sleeping</li><li style="text-align:justify">Vomiting*, stomach ache, diarrhoea, indigestion, wind</li><li style="text-align:justify">Rash, itching</li><li style="text-align:justify">Muscle stiffness</li><li style="text-align:justify">Difficulty swallowing*</li><li style="text-align:justify">Worsening of existing allergies</li></ul><p style="text-align:justify"><strong>Uncommon: may affect up to 1 in 100 people</strong></p><ul><li style="text-align:justify">Stroke*</li><li style="text-align:justify">Heart failure, palpitations (awareness of heart beat), fast heart rate</li><li style="text-align:justify">Worsening of existing high blood pressure</li><li style="text-align:justify">Abnormalities in liver-related blood tests</li><li style="text-align:justify">Abnormalities in kidney-related blood tests</li><li style="text-align:justify">Anaemia (changes in red blood cells that can cause fatigue and breathlessness)</li><li style="text-align:justify">Anxiety, depression, tiredness, drowsiness, tingling sensations (pins and needles)</li><li style="text-align:justify">High levels of potassium in blood test results (can cause nausea (feeling sick), fatigue, muscle weakness or palpitations)</li><li style="text-align:justify">Impaired or blurred vision, ringing in the ears, mouth pain and sores, difficulty hearing*</li><li style="text-align:justify">Constipation, burping, stomach inflammation (indigestion, stomach ache or vomiting), worsening of inflammation of the stomach or intestine.</li><li style="text-align:justify">Leg cramps</li><li style="text-align:justify">Raised itchy rash (hives)</li></ul><p style="text-align:justify"><strong>Rare: may affect up to 1 in 1,000 people</strong></p><ul><li style="text-align:justify">Ulcers (bleeding) in the stomach, gullet or intestines; or rupture of the intestine (can cause stomach ache, fever, nausea, vomiting, intestinal blockage), dark or black stools, inflammation of the gullet (can cause difficulty in swallowing), inflammation of the pancreas (can lead to stomach pain)</li><li style="text-align:justify">Reduced number of white blood cells (which help protect the body from infection) and blood platelets (increased chance of bleeding or bruising)</li><li style="text-align:justify">Difficulty coordinating muscular movements</li><li style="text-align:justify">Feeling confused, changes in the way things taste</li><li style="text-align:justify">Increased sensitivity to light</li><li style="text-align:justify">Loss of hair</li></ul><p style="text-align:justify"><strong>Not known: frequency cannot be estimated from the available data</strong></p><ul><li style="text-align:justify">Bleeding within the brain causing death</li><li style="text-align:justify">Serious allergic reactions (including potentially fatal anaphylactic shock) which can cause skin rash, swelling of the face, lips, mouth, tongue or throat, wheezing or difficulty breathing; difficulty swallowing</li><li style="text-align:justify">Bleeding of the stomach or intestines (can lead to bloody stools or vomiting), inflammation of the intestine or colon, nausea (feeling sick)</li><li style="text-align:justify">Serious skin conditions such as Stevens-Johnson syndrome, exfoliative dermatitis and toxic epidermal necrolysis (can cause rash, blistering or peeling of the skin) and acute generalised exenthematous pustulosis (red swollen area with numerous small pustules)</li><li style="text-align:justify">Liver failure, liver damage and severe liver inflammation (sometimes fatal or requiring liver transplant). Symptoms may include nausea (feeling sick), diarrhoea, jaundice (yellow discolouration of the skin or eyes), dark urine, pale stools, bleeding easily, itching or chills</li><li style="text-align:justify">Kidney problems (possible kidney failure, inflammation of the kidneys)</li><li style="text-align:justify">Blood clot in the blood vessels in the lungs. Symptoms may include sudden breathlessness, sharp pains when you breathe or collapse</li><li style="text-align:justify">Irregular heartbeat</li><li style="text-align:justify">Meningitis (inflammation of the membrane around the brain and spinal cord)</li><li style="text-align:justify">Hallucinations</li><li style="text-align:justify">Worsening of epilepsy (possible more frequent and/or severe seizures)</li><li style="text-align:justify">Inflamed blood vessels (can cause fever, aches, purple blotches on the skin)</li><li style="text-align:justify">Blockage of an artery or vein in the eye leading to partial or complete loss of vision, inflammation of the conjunctiva, bleeding in the eye</li><li style="text-align:justify">A reduction in the number of red and white blood cells and platelets (may cause tiredness, easy bruising, frequent nose bleeds and increased risk of infections)</li><li style="text-align:justify">Chest pain</li><li style="text-align:justify">Impaired sense of smell</li><li style="text-align:justify">Skin discolouration (bruising), muscle pain and weakness, painful joints</li><li style="text-align:justify">Menstrual disturbances</li><li style="text-align:justify">Headache, flushing</li><li style="text-align:justify">Low levels of sodium in blood test results (can cause loss of appetite, headache, nausea (feeling sick), muscle cramps and weakness)</li></ul><p style="text-align:justify">In clinical studies not associated with Arthritis or other arthritic conditions, where celecoxib was taken at doses of 400 mg per day for up to 3 years, the following additional side effects have been observed:</p><p style="text-align:justify"><strong>Common: may affect up to 1 in 10 people</strong></p><ul><li style="text-align:justify">Heart problems: angina (chest pain)</li><li style="text-align:justify">Stomach problems: irritable bowel syndrome (can include stomach ache, diarrhoea, indigestion, wind)</li><li style="text-align:justify">Kidney stones (which may lead to stomach or back pain, blood in urine), difficulty passing urine</li><li style="text-align:justify">Weight gain</li></ul><p style="text-align:justify"><strong>Uncommon: may affect up to 1 in 100 people</strong></p><ul><li style="text-align:justify">Deep vein thrombosis (blood clot usually in the leg, which may cause pain, swelling or redness of the calf or breathing problems)</li><li style="text-align:justify">Stomach problems: stomach infection (which can cause irritation and ulcers of the stomach and intestines),</li><li style="text-align:justify">Lower limb fracture</li><li style="text-align:justify">Shingles, skin infection, eczema (dry itchy rash), pneumonia (chest infection (possible cough, fever, difficulty breathing))</li><li style="text-align:justify">Floaters in the eye causing blurred or impaired vision, vertigo due to inner ear troubles, sore, inflamed or bleeding gums, mouth sores</li><li style="text-align:justify">Excessive urination at night, bleeding from piles/ haemorrhoids, frequent bowel movements</li><li style="text-align:justify">Fatty lumps in skin or elsewhere, ganglion cyst (harmless swellings on or around joints and tendons in the hand or foot), difficulty speaking, abnormal or very heavy bleeding from the vagina, breast pain</li><li style="text-align:justify">High levels of sodium in blood test results</li></ul><p style="text-align:justify">If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the blister and carton after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.<br />Do not store above 30o C.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is celecoxib. Each capsule contains 200 mg celecoxib.<br />- The other ingredients (excipients) are: lactose monohydrate, croscarmellose sodium, povidone K30, sodium lauryl sulphate, magnesium stearate. Capsules 200 mg shells contain gelatin, titanium dioxide (E171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CEBO 200 mg capsules, are hard capsules with white cap and white body.
CEBO 200 mg is available in blisters packs of 20 capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><br />AJA Pharmaceutical Industries Company, Ltd.<br />Saudi Arabia, Riyadh<br />The Business Gate, Cordoba<br />G Floor, Zone C2,</p><p><strong>Manufacturers</strong><br />Atlantic Pharma &ndash; Produ&ccedil;&otilde;es Farmac&ecirc;uticas, S.A.<br />Rua da Tapada Grande, n.&ordm; 2; Abrunheira, 2710-089 Sintra, Portugal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="text-align:justify">يحتوي سيبو على المادة الفعالة سيليكوكسيب</p><p dir="RTL" style="text-align:justify">يستعمل سيبو لتخفيف أعراض <strong>إلتهاب المفاصل الروماتزمي</strong> و<strong>التهابات المفاصل</strong> و<strong>التهاب الفقار الرثياني</strong>.</p><p dir="RTL" style="text-align:justify">ينتمي سيبو إلى مجموعة من المنتجات الدوائية تسمى مضادات الإلتهاب غير السترويدية (NSAIDS).</p><p dir="RTL" style="text-align:justify">وينتمي تحديداً إلى مجموعة فرعية تسمى مثبطات كوكس-2.</p><p dir="RTL" style="text-align:justify">يقوم الجسم بإنتاج البروستاجلاندينات التي يمكن أن تسبب الألم والإلتهاب. وفي حالات مثل التهاب المفاصل الروماتزمي والتهابات المفاصل فإن الجسم ينتج المزيد من تلك المواد.</p><p dir="RTL" style="text-align:justify">سيبو يعطي مفعوله من خلال تقليل إنتاج البروستاجلاندينات وبالتالي يخفف الألم والإلتهابات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">لقد تم وصف سيبو لك من قبل الطبيب. والمعلومات التالية سوف تساعدك في الحصول على أفضل النتائج باستخدام سيبو. إذا كان لديك المزيد من الأسئلة فيرجى الإتصال بالطبيب أو الصيدلي.</p><p dir="RTL" style="text-align:justify"><strong>لا تتناول سيبو في الحالات التالية:</strong></p><p dir="RTL" style="text-align:justify">أبلغ طبيبك إذا كان لديك أي من الحالات التالية حيث أن المرضى الذين يعانون من تلك الحالات يجب أن لا يستعملوا سيبو:</p><ul dir="rtl"><li style="text-align:justify">إذا كانت لديك حساسية لـ &quot;سيليكوكسيب&quot; أو أي من مكونات هذا الدواء (المدرجة في الفقرة رقم-6).</li><li style="text-align:justify">إذا كانت لديك حساسية لمجموعة من الأدوية التي تسمى السلفوناميدات (مثل بعض المضادات الحيوية التي تستخدم لعلاج الإصابات أو العدوى).</li><li style="text-align:justify">إذا كنت تعاني من قرحة أو نزيف بالمعدة أو الأمعاء.</li><li style="text-align:justify">إذا كنت نتيجة استعمال حامض الأسيتيل سالساليك (الأسبرين) أو أي دواء آخر من مضادات الإلتهاب غير السترويدية (NSAIDS) قد أصبت بالربو، أو سليلات بالأنف، أو احتقان شديد بالأنف، أو ردة فعل حساسية مثل الطفح الجلدي المصحوب بالحكة، أو انتفاخ الوجه أو الشفتين أو اللسان أو الحلق، أو صعوبة في التنفس أو أزيز تنفسي.</li><li style="text-align:justify">بالنسبة للنساء إذا كانت حاملاً. أما إذا كان هناك احتمال لحدوث الحمل أثناء استعمال هذا الدواء فيجب مناقشة طرق منع الحمل المناسبة مع الطبيب.</li><li style="text-align:justify">اذا كانت المرأة ترضع. &nbsp;</li><li style="text-align:justify">إذا كنت تعاني من مرض شديد بالكبد.</li><li style="text-align:justify">إذا كنت تعاني من مرض شديد بالكلى.</li><li style="text-align:justify">إذا كنت تعاني من مرض التهابي بالأمعاء مثل التهاب القولون التقرحي أو &quot;مرض كرون&quot;.</li><li style="text-align:justify">إذا كنت تعاني من فشل القلب أو شخصت إصابتك بمرض القلب الإحتشائي، أو مرض في القلب والأوعية الدموية، أو شخصت إصابتك بنوبة قلبية، أو جلطة، أو نوبة قلبية احتشائية مؤقتة (نقص مؤقت في تدفق الدم للدماغ والتي تعرف أيضا بـ &quot;الجلطة الصغيرة&quot;)، أو الذبحة الصدرية، أو انسداد أو إعاقة لتدفق الدم إلى القلب أو إلى الدماغ.</li><li style="text-align:justify">اذا كنت مصاباً او أصبت في السابق بمشاكل في الدورة الدموية (مرض الشرايين الطرفية) أو أجريت لك جراحة في شرايين الرجلين.</li></ul><p style="text-align:justify"><strong>تحذيرات واحتياطات:</strong></p><p dir="RTL" style="text-align:justify"><strong>عليك استشارة الطبيب أو الصيدلي أو الممرضة قبل تناول &quot;سيبو&quot; في الحالات التالية:</strong></p><ul dir="rtl"><li style="text-align:justify">إذا كان لديك تاريخ للإصابة بقرحة أو نزيف في المعدة أو الأمعاء.</li><li style="text-align:justify"><strong>(لا تستعمل سيبو)</strong> اذا كنت تعاني <strong>حالياً</strong> من قرحة أو نزيف في المعدة أو الأمعاء.</li><li style="text-align:justify">إذا كنت تستعمل حامض الأسيتيل سالساليك (الأسبرين) ولو بجرعات منخفضة لوقاية القلب.</li><li style="text-align:justify">إذا كنت تستعمل أدوية لمنع أو خفض تجلط الدم (مثل الوارفرين).</li><li style="text-align:justify">إذا كنت تستعمل سيبو مع أي نوع آخر من مضادات الإلتهاب غير السترويدية (NSAIDS) غير الأسبرين فيجب تفادي استعمال هذه الأنواع معا في نفس الوقت.</li><li style="text-align:justify">إذا كنت تدخن السجائر أو كنت مصابا بمرض السكري أو ارتفاع ضغط الدم أو ارتفاع في مستوى الكولسترول بالدم.</li><li style="text-align:justify">إذا كان القلب أو الكبد أو الكلى لديك لا تعمل بصورة جيدة فإن الطبيب قد يقرر أن يجري لك فحوصات منتظمة.</li><li style="text-align:justify">إذا كنت تعاني من احتباس السوائل في الجسم (كما في حالة تورم الكاحلين والقدمين).</li><li style="text-align:justify">إذا كنت تعاني من الجفاف نتيجة المرض أو الإسهال أو استعمال مدرات البول مثلاً (التي تستعمل للتخلص من السوائل الزائدة في الجسم).</li><li style="text-align:justify">إذا كنت تعاني من ردة فعل حساسية شديدة أو طفح جلدي من جراء استعمال أي نوع من الأدوية.</li><li style="text-align:justify">إذا كنت تشعر بالمرض من جراء عدوى أو تظن أن لديك عدوى حيث أن سيبو قد يحجب الحمى أو غيرها من أعراض العدوى أو الالتهاب.</li><li style="text-align:justify">إذا كان عمرك يزيد عن 65 عاماً فإن الطبيب قد يقرر أن يجري لك فحوصات منتظمة.</li></ul><p dir="RTL" style="text-align:justify">إن هذا الدواء مثل غيره من مضادات الإلتهاب غير السترويدية (NSAIDS) قد يسبب ارتفاع ضغط الدم، وبالتالي فإن الطبيب يمكن أن يقوم بمراقبة ضغط دمك من خلال قياسه على فترات منتظمة.</p><p dir="RTL" style="text-align:justify">هناك تقارير ذكرت بعض حالات من ردود الفعل الشديدة في الكبد بما فيها التهاب شديد في الكبد، وحالات تلف في الكبد وفشل كبدي (وبعضها أدت إلى الوفاة أو استدعت إجراء زراعة للكبد) من جراء استعمال سيليكوكسيب.</p><p dir="RTL" style="text-align:justify">ومن تلك الحالات التي ذكر فيها وقت ظهور تلك الأعراض فإن أشد الأعراض أو ردود الفعل الكبدية حدثت خلال شهر واحد من بدء استعمال العلاج.</p><p dir="RTL" style="text-align:justify">قد يؤدي سيبو إلى جعل حدوث الحمل أكثر صعوبة. &nbsp;فإذا كانت المرأة تخطط لحدوث الحل أو أنها تواجه مصاعب في حدوث الحمل&nbsp; فيجب أن تبلغ الطبيب (أنظر الجزء الخاص بالحمل والإرضاع).</p><p dir="RTL" style="text-align:justify"><strong>الأدوية الأخرى و سيبو:</strong></p><p dir="RTL" style="text-align:justify">بعض الأدوية تؤثر في مفعول أو طريقة عمل أدوية أخرى.</p><p dir="RTL" style="text-align:justify">يرجى استشارة الطبيب أو الصيدلي إذا كنت تستعمل أو استعملت حديثا أو يتوقع أن تستخدم أي أدوية أخرى:</p><ul dir="rtl"><li style="text-align:justify">دكستروميثورفان (يستعمل لعلاج السعال).</li><li style="text-align:justify">الأدوية التي تعرف بمثبطات &quot;ايه سي إي&quot; أو معطلات انجيوستين-2 (التي تستعمل للسيطرة على ضغط الدم المرتفع وفشل القلب).</li><li style="text-align:justify">مدرات البول (ادوية تستعمل للتخلص من السوائل الزائدة بالجسم).</li><li style="text-align:justify">فلوكونازول وريفامبيسين (تستعمل لعلاج الإصابة بالفطريات والبكتيريا).</li><li style="text-align:justify">الورافرين وغيره من مضادات التخثر التي تؤخذ بالفم (تزيد من سيولة الدم لخفض التجلط).</li><li style="text-align:justify">ريفامبيسين (مضاد حيوي).</li><li style="text-align:justify">الليثيوم (وهو دواء يستعمل لعلاج بعض أنواع الاكتئاب).</li><li style="text-align:justify">أدوية أخرى تستعمل لعلاج الاكتئاب أو اضطرابات النوم أو ارتفاع ضغط الدم أو عدم انتظام النبض.</li><li style="text-align:justify">المهدئات العصبية أو مضادات الذهان (التي تستعمل لعلاج بعض الأمراض العصبية).</li><li style="text-align:justify">ميثوتريكسات (يستعمل لعلاج التهاب المفاصل الروماتزمي، والصدفية، وابيضاض الدم &quot;اللوكيميا&quot;).</li><li style="text-align:justify">كاربامازيبين (دواء يستعمل لعلاج الصرع/التشنجات وبعض انواع الألم أو الاكتئاب).</li><li style="text-align:justify">الباربتيورات (دواء يستعمل لعلاج الصرع/التشنجات وبعض حالات اضطرابات النوم).</li><li style="text-align:justify">سيكلوسبورين و تاطكروليماس (دواء يستعمل كخافض للمناعة بعد عمليات زراعة الأعضاء مثلا).</li><li style="text-align:justify">يمكن تناول سيبو مع جرعات منخفضة (75ملجم أو أقل يومياً) من حامض الأستيل سالساليك (الأسبرين)، عليك استشارة الطبيب قبل أن تستعمل هذين الدوائين معاً.</li><li style="text-align:justify">لا تتتناول جرعات عالية من الأسبرين أو أدوية أخرى مضادة للإلتهابات في آن واحد مع سيبو.</li></ul><p dir="RTL" style="text-align:justify"><strong>الحمل والإرضاع والخصوبة: </strong></p><p dir="RTL" style="text-align:justify">يجب عدم إعطاء سيبو للنساء الحوامل أو اللاتي يمكن أن يحدث لديهن الحمل (النساء في سن الإنجاب اللاتي لا يستعمل موانع حمل ملائمة) أثناء استعمال العلاج.</p><p dir="RTL" style="text-align:justify">وفي حالة حدوث الحمل أثناء استعمال سيبو فيجب وقفه على الفور واستشارة الطبيب لأجل الحصول على علاج بديل.</p><p dir="RTL" style="text-align:justify">ويجب عدم إعطاء سيبو للنساء المرضعات.&nbsp;</p><p dir="RTL" style="text-align:justify">النساء الحوامل أو المرضعات أو اللاتي يعتقدن أنهن حوامل أو يخططن لحدوث الحمل يجب عليهن استشارة الطبيب أو الصيدلي قبل استعمال هذا الدواء.</p><p dir="RTL" style="text-align:justify"><strong>قيادة المركبات وتشغيل الآليات: </strong></p><p dir="RTL" style="text-align:justify">فيجب عليك معرفة تأثير سيبو عليك قبل قيادة أي مركبات أو تشغيل أي آليات فإذا حدثت لديك أعراض نعاس أو دوار بعد استعمال سيبو، فيجب الامتناع عن قيادة أي مركبات أو تشغيل أي آليات حتى تزول تلك التأثيرات.</p><p dir="RTL" style="text-align:justify"><strong>سيبو</strong> <strong>يحتوي على اللاكتوز</strong>:</p><p dir="RTL" style="text-align:justify">إذا كان طبيبك قد أبلغك بأن لديك عدم تقبل لبعض أنواع السكريات فيجب عليك الإتصال بالطبيب قبل تناول هذا الدواء.</p><p style="text-align:justify">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">يجب عليك دائما استعمال هذا الدواء حسب تعليمات الطبيب أو الصيدلي تماما. وإذا كنت غير متأكد فيجب عليك الإتصال بالطبيب أو الصيدلي. وإذا كنت تشعر أو تظن أن تأثير سيبو عليك شديد أو ضعيف فيجب عليك استشارة الطبيب أو الصيدلي.</p><p dir="RTL" style="text-align:justify">سيخبرك الطبيب بالجرعة التي عليك أن تأخذها. وحيث أن مخاطر التأثيرات الجانبية المتعلقة بمشاكل القلب يمكن أن تزيد بحسب مقدار الجرعة وطول مدة الاستعمال فمن المهم أن تأخذ أقل جرعة ممكنة تكفي لتسكين الألم ولا تستعمل هذا الدواء لفترة أطول مما هو ضروري.</p><p dir="RTL" style="text-align:justify"><strong>يجب ابتلاع سيبو كاملا دون مضغ مع الماء أو أي نوع من الشراب:</strong> ويمكن أخذ الكبسولات في أي وقت خلال اليوم مع الطعام أو بدونه، ومن الأفضل أن تأخذ الجرعة في الوقت نفسه من كل يوم.</p><p dir="RTL" style="text-align:justify">عليك استشارة الطبيب اذا لم تشعر بأي فائدة خلال أسبوعين من البدء في العلاج.</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;الجرعة:</strong></p><p dir="RTL" style="text-align:justify"><u>كبسولة 200ملغم صلبة:</u></p><p dir="RTL" style="text-align:justify"><strong>لحالات التهاب المفاصل:</strong></p><p dir="RTL" style="text-align:justify">الجرعة الابتدائية اليومية الموصى بها هي 200 ملغم <strong>(كبسولة واحدة صلبة مرة واحدة في اليوم)</strong> ويمكن ان يقوم الطبيب بزيادتها إلى 400 ملغم كحد اقصى (<strong>كبسولة واحدة صلبة مرتين في اليوم</strong>) إذا دعت الحاجة.</p><p dir="RTL" style="text-align:justify"><strong>لحالات التهاب المفاصل الروماتزمي:</strong></p><p dir="RTL" style="text-align:justify">الجرعة الابتدائية اليومية الموصى بها هي 200 ملغم <strong>(كبسولة واحدة صلبة مرة واحدة في اليوم)</strong> ويمكن أن يقوم الطبيب بزيادتها إلى 400 ملغم كحد اقصى (<strong>كبسولة واحدة صلبة مرتين في اليوم</strong>) إذا دعت الحاجة.</p><p dir="RTL" style="text-align:justify"><strong>لحالات الالتهاب الفقاري القسطي:</strong></p><p dir="RTL" style="text-align:justify">الجرعة الابتدائية اليومية الموصى بها هي 200 ملغم <strong>(كبسولة واحدة صلبة مرة واحدة في اليوم)</strong> ويمكن أن يقوم الطبيب بزيادتها إلى 400 ملغم كحد اقصى (<strong>عدد2 كبسولة صلبة مرة واحدة يوميا أو كبسولة واحدة صلبة مرتين يومياً</strong>) إذا دعت الحاجة.</p><p dir="RTL" style="text-align:justify"><strong>مشاكل الكبد</strong> <strong>أو الكلى:</strong></p><p dir="RTL" style="text-align:justify">إذا كنت تعاني من مشاكل في الكبد أو الكلى فيجب أن تبلغ الطبيب بذلك حيث أنه قد يلزمك جرعات اخفض.</p><p dir="RTL" style="text-align:justify"><strong>الاستعمال لدى كبار السن خاصة الذين يقل وزنهم عن 50 كجم</strong>:</p><p dir="RTL" style="text-align:justify">إذا كان عمرك اكثر من 65 عاماً وخاصة إذا كان وزنك أقل من 50 كجم فإن الطبيب قد يقرر مراقبة حالتك بصورة وثيقة.</p><p dir="RTL" style="text-align:justify"><strong>الاستعمال لدى الأطفال</strong>:</p><p dir="RTL" style="text-align:justify">سيبو مخصص للبالغين فقط وهو غير مخصص للأطفال.</p><p dir="RTL" style="text-align:justify"><strong>إذا تناولت جرعة زائدة من سيبو</strong>:</p><p dir="RTL" style="text-align:justify">يجب أن لا تتناول من كبسولات سيبو أكثر مما يصفه لك الطبيب.</p><p dir="RTL" style="text-align:justify">إذا تناولت من كبسولات سيبو زيادة عن وصفة الطبيب فيجب عليك الاتصال بالطبيب أو الصيدلي أو المستشفى على وجه السرعة وأن تأخذ الدواء معك.</p><p dir="RTL" style="text-align:justify"><strong>إذا نسيت أن تتناول سيبو</strong>:</p><p dir="RTL" style="text-align:justify">إذا نسيت أن تتناول الجرعة المعتادة في وقتها فيجب عليك أن تأخذ تلك الجرعة حالما تتذكرها إلا إذا كان قد حل وقت تناول الجرعة التالية وفي هذه الحالة خذ الجرعة التالية التي حل موعدها وواصل الاستعمال كالمعتاد. ويجب أن لا تضاعف الجرعة لتعوض الجرعة التي نسيتها.</p><p dir="RTL" style="text-align:justify"><strong>إذا توقفت عن تتناول سيبو</strong>:</p><p dir="RTL" style="text-align:justify">إن التوقف فجأة عن تناول الدواء قد يؤدي إلى تفاقم الأعراض. وبالتالي يجب أن لا تتوقف عن استعمال سيبو ما لم ينصحك الطبيب بذلك.</p><p dir="RTL" style="text-align:justify">وقد يقوم الطبيب بتخفيض الجرعة لبضعة أيام قبل أن يقرر التوقف عن استعمال الدواء تماماً.</p><p dir="RTL" style="text-align:justify">وإذا كانت لديك أي اسئلة او استفسارات حول استعمال هذا الدواء فيجب عليك استشارة الطبيب أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">هذا الدواء كغيره من الأدوية يمكن أن يسبب بعض التأثيرات الجانبية مع أنها لا تحدث لدى جميع الأشخاص.</p><p style="text-align:justify">التأثيرات الجانبية المذكورة أدناه تمت ملاحظتها لدى المرضى المصابين بالتهابات المفاصل الذين استعملوا سيليكوكسيب. التأثيرات الجانبية التي تظهر عليها علامة النجمة (*) تمثل أعلى معدلات حدوث لدى المرضى الذين استعملوا سيليكوكسيب&nbsp; لمنع الإصابة بالسليلات المخاطية في القولون. والمرضى المشمولين بهذه الدراسات استعملوا سيليكوكسيب بجرعات عالية ولمدة طويلة.</p><p style="text-align:justify">إذا حدث لك أي من التأثيرات التالية فيجب التوقف عن استعمال سيبو والاتصال بالطبيب فوراً.</p><ul><li style="text-align:justify">ردة فعل حساسية مثل طفح جلدي أو تورم في الوجه أو ازيز تنفسي أو صعوبة في التنفس.</li><li style="text-align:justify">مشاكل في القلب مثل الألم بالصدر</li><li style="text-align:justify">ألم شديد أو أي علامات على حدوث النزيف من المعدة أو الأمعاء مثل خروج غائط أسود أو مختلط بالدم أو تقيؤ الدم.</li><li style="text-align:justify">ردة فعل بالجلد مثل الطفح أو النفط أو تقشر الجلد.</li><li style="text-align:justify">فشل الكبد (وتشمل أعراضه الغثيان، الإسهال، اليرقان &quot;تحول لون الجلد وبياض العيينين إلى اللون الأصفر&quot; ).</li><li style="text-align:justify">تأثيرات شائعة جداً: يمكن ان تصيب ما يزيد عن 1 من بين كل 10 اشخاص</li><li style="text-align:justify">ارتفاع ضغط الدم.</li></ul><p style="text-align:justify"><strong>تأثيرات شائعة: يمكن ان تصيب لغاية 1 من بين كل 10 اشخاص</strong></p><ul><li style="text-align:justify">نوبة قلبية*.</li><li style="text-align:justify">تجمع السوائل في الجسم يتمثل في تورم الكاحلين والرجلين و/أو اليدين.</li><li style="text-align:justify">إصابة (عدوى) في المسالك البولية.</li><li style="text-align:justify">ضيق في التنفس*، التهاب الجيوب الأنفية (التهاب الجيوب، عدوى في الجيوب، انسداد أو ألم في الجيوب)، انسداد الأنف (الزكام) أو الرشح، التهاب الحلق، السعال، نزلات البرد، أعراض شبيهة بالأنفلونزا.</li><li style="text-align:justify">دوار، مصاعب في النوم.</li><li style="text-align:justify">تقيؤ*، ألم بالمعدة، إسهال، عسر الهضم، خروج غازات.</li><li style="text-align:justify">طفح جلدي، حكة.</li><li style="text-align:justify">تصلب في العضلات.</li><li style="text-align:justify">صعوبة في البلع*.</li><li style="text-align:justify">تفاقم الحساسية الموجودة أصلاً.</li></ul><p style="text-align:justify"><strong>تأثيرات غير شائعة: يمكن ان تصيب لغاية 1 من بين كل 100 شخص</strong></p><ul><li style="text-align:justify">سكتة (جلطة) دماغية.</li><li style="text-align:justify">فشل القلب، خفقان (الإحساس بنبض القلب)، تسارع النبض.</li><li style="text-align:justify">تفاقم ارتفاع ضغط الدم الموجود أصلاً.</li><li style="text-align:justify">نتائج غير طبيعية لفحوصات وتحاليل دم تتعلق بالكبد.</li><li style="text-align:justify">نتائج غير طبيعية لفحوصات وتحاليل دم تتعلق بالكلى.</li><li style="text-align:justify">فقر الدم أو الأنيميا ( تغيرات في كريات الدم الحمراء، يمكن أن تسبب الإعياء وضعف أو انقطاع التنفس).</li><li style="text-align:justify">قلق، اكتئاب، تعب، نعاس، احساس بالتنميل (مثل الوخز بالدبابيس او الإبر).</li><li style="text-align:justify">ارتفاع مستوى البوتاسيوم في الدم (يمكن أن يسبب الغثيان، أو الإعياء، أو ضعف العضلات، أو الخفقان).</li><li style="text-align:justify">ضعف أو ضبابية في الرؤيا، طنين في الأذن، الم والتهاب بالفم، صعوبة في السمع*.</li><li style="text-align:justify">إمساك، تجشؤ، التهاب المعدة(عسر الهضم أو ألم بالمعدة أو تقيؤ) تفاقم التهابات المعدة أو الأمعاء الموجودة أصلاً.</li><li style="text-align:justify">تشنجات عضلية بالأرجل.</li><li style="text-align:justify">طفح جلدي بارز مصحوب بالحكة (الشرى).</li></ul><p style="text-align:justify"><strong>تأثيرات نادرة: يمكن ان تصيب لغاية 1 من بين كل 1000 شخص</strong></p><ul><li style="text-align:justify">قروح (نزيف) بالمعدة أو المريء أو الأمعاء، أو حدوث خرق أو انفجار بالأمعاء(يمكن أن يؤدي إلى ألم بالمعدة وحمى وغثيان وتقيؤ أو انسداد الأمعاء)، براز داكن أو أسود اللون، التهاب المريء (يمكن أن يسبب صعوبة في البلع)، التهاب البنكرياس (يمكن أن يتسبب في ألم بالمعدة).</li><li style="text-align:justify">انخفاض تعداد كريات الدم البيضاء (التي تساعد على حماية الجسم من الإصابات أو العدوى)، والصفائح الدموية (زيادة احتمالات حدوث النزيف أو الكدمات).</li><li style="text-align:justify">صعوبة في تناسق أو توافق حركة العضلات.</li><li style="text-align:justify">شعور بالإرتباك والتشوش، تغير في طعم الأشياء.</li><li style="text-align:justify">زيادة الحساسية للضوء.</li><li style="text-align:justify">فقدان أو تساقط الشعر.</li></ul><p style="text-align:justify"><strong>تأثيرات غير معروفة: لا يمكن تقدير معدلات أو وتيرة الحدوث من واقع البيانات المتوفرة</strong></p><ul><li style="text-align:justify">نزيف بالدماغ يؤدي إلى الوفاة.</li><li style="text-align:justify">ردود فعل حساسية شديدة (بما في ذلك الصدمة الإستهدافية المميتة) والتي تسبب ظهور طفح جلدي وتورم الوجه والشفتين واللسان أو الحلق، وأزيز تنفسي أو صعوبة في التنفس ، وصعوبة في البلع.</li><li style="text-align:justify">نزيف بالمعدة أو الأمعاء (يمكن أن يؤدي إلى براز أو تقيؤ مختلطة بالدم)، والتهاب الأمعاء أو القولون، والغثيان.</li><li style="text-align:justify">تأثيرات خطيرة بالجلد مثل متلازمة ستيفنز-جونسون، التهاب البشرة التقشري، ظهور نفط بالجلد أو تقشر الجلد، تنفط صفراوي حاد عام (منطقة تورم محمرة بها عدد كبير من النفط الصغيرة).&nbsp;</li><li style="text-align:justify">فشل الكبد، تلف بالكبد مع التهاب كبدي شديد (احيانا يؤدي للوفاة او يستدعي عملية زراعة كبد). الأعراض قد تشمل الغثيان، والإسهال، واليرقان (اصفرار بالجلد والعيون)، نزول بول داكن، خروج براز باهت اللون، سهولة النزيف، الحكة، نوبات قشعريرة.</li><li style="text-align:justify">مشاكل في الكلى (احتمال فشل كلوي التهاب الكلى.</li><li style="text-align:justify">تكون جلطات بالأوعية الدموية بالرئتين. وقد تشمل الأعراض انقطاع مفاجئ للتنفس، أو آلام حادة عند التنفس، او الانهيار.</li><li style="text-align:justify">عدم انتظام النبض.</li><li style="text-align:justify">التهاب السحايا (التهاب الغشاء المغلف لكل من الدماغ والحبل الشوكي).</li><li style="text-align:justify">نوبات هلوسة.</li><li style="text-align:justify">تفاقم الصرع (احتمال زيادة حدوث نوبات التشنج و/او زيادة شدة التشنجات)</li><li style="text-align:justify">التهاب الأوعية الدموية (يمكن أن يسبب الحمى والأوجاع وظهور بقع ارجوانية اللون على الجلد.</li><li style="text-align:justify">انسداد شريان أو وريد بالعين يؤدي إلى فقدان كامل أو جزئي للبصر، التهاب ملتحمة العين، نزيف بالعين.</li><li style="text-align:justify">انخفاض تعداد كريات الدم الحمراء والبيضاء والصفائح الدموية (قد يسبب التعب وسهولة حدوث الكدمات ونزيف متكرر من الأنف وزيادة مخاطر العدوى).</li><li style="text-align:justify">ألم بالصدر.</li><li style="text-align:justify">تعطل حاسة الشم.</li><li style="text-align:justify">تغير لون الجلد (كدمات)، آلام وضعف بالعضلات، آلام بالمفاصل.</li><li style="text-align:justify">اضطرابات بالدورة الشهرية.</li><li style="text-align:justify">صداع واحمرار الوجه.</li><li style="text-align:justify">انخفاض مستويات الصوديوم بالدم (يمكن ان يؤدي إلى فقدان الشهية، الصداع، الغثيان، تقلصات وضعف بالعضلات).</li></ul><p dir="RTL" style="text-align:justify">في تجارب سريرية غير مرتبطة بالتهاب المفاصل أو غيرها من حالات المفاصل عندما أعطي سيليكوكسيب بجرعات 400 ملغم يوميا لمدة تصل إلى 3 سنوات تمت ملاحظة التأثيرات الجانبية الإضافية التالية:</p><p style="text-align:justify"><strong>تأثيرات شائعة: يمكن أن تصيب لغاية 1 من بين كل 10 اشخاص</strong></p><ul><li style="text-align:justify">مشاكل في القلب: ذبحة صدرية (ألم بالصدر).</li><li style="text-align:justify">مشاكل في البطن: متلازمة القولون العصبي(يمكن أن يشتمل على ألم بالمعدة، إسهال، عسر الهضم، خروج غازات).</li><li style="text-align:justify">حصوات بالكلى (قد تؤدي إلى آلام في البطن أو الظهر، نزول دم في البول)، صعوبة في التبول.</li><li style="text-align:justify">زيادة (اكتساب) الوزن.</li></ul><p style="text-align:justify"><strong>تأثيرات غير شائعة: يمكن أن تصيب لغاية 1 من بين كل 100 شخص</strong></p><ul><li style="text-align:justify">جلطات وريدية عميقة (جلطات دموية عادة في الأرجل والتي تسبب الألم والتورم واحمرار ربلة الساق أو صعوبات في التنفس).</li><li style="text-align:justify">مشاكل في البطن: إصابة (عدوى) في المعدة قد تسبب التهيج والحرقان والقروح بالمعدة والأمعاء)</li><li style="text-align:justify">كسور بالطرفين السفليين.</li><li style="text-align:justify">الهربس، إصابات جلدية، اكزيما (طفح جاف مصحوب بحكة) التهاب رئوي (إصابة بالصدر قد يصاحبها سعال وحمى وصعوبة في التنفس.</li><li style="text-align:justify">غشاوة في العيون قد تؤدي إلى ضبابية أو ضعف شديد بالنظر، دوار وترنح نتيجة مشاكل في الأذن الداخلية، التهاب ونزيف من اللثة، التهابات بالفم.</li><li style="text-align:justify">زيادة التبول الليلي، نزيف من البواسير، زيادة في التبرز.</li><li style="text-align:justify">كتل دهنية في الجلد أو أماكن أخرى، تكيس عقدي (تورم غير ضار في المفاصل أو الأوتار أو حولها في اليدين أو القدمين)، صعوبة في الكلام، نزيف غير طبيعي أو غزير جداً من المهبل ، ألم بالثديين.</li><li style="text-align:justify">ارتفاع مستوى الصوديوم في الدم حسب نتائج التحاليل.&nbsp;</li></ul><p style="text-align:justify"><strong>الإبلاغ عن الآثار الجانبية:</strong></p><p style="text-align:justify">إذا ظهرت لديك أي من التأثيرات الجانبية فيجب أن تبادر بالتحدث إلى الطبيب أو الصيدلي أو الممرضة. وتشمل تلك الأعراض اي تأثيرات محتملة اخرى لم يرد ذكرها في هذه النشرة.</p><p style="text-align:justify">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">احفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL" style="text-align:justify">لا تستعمل سيبو بعد تاريخ انتهاء صلاحيته المطبوع على العلبة وهو يشير إلى آخر يوم في ذلك الشهر.</p><p dir="RTL" style="text-align:justify">لا تخزنه في درجات حرارة تزيد عن 30 درجة مئوية.</p><p dir="RTL" style="text-align:justify">لا تلقي بأي دواء في مياه الصرف الصحي أو في النفايات المنزلية. وعليك أن تسأل الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاجها. وهذه التدابير تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي &quot;سيليكوكسيب&quot;.</p><p dir="RTL" style="text-align:justify">كل كبسولة من سيبو المغلف تحتوي على 200 ملغم من مادة سيليكوكسيب.</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى (المسوغات) هي:</p><p dir="RTL" style="text-align:justify">لاكتوز أحادي مائي، هيبروميلوز صوديوم،&nbsp; بروفيدون كي-30، كبريتات لوريل الصوديوم، &nbsp;ستيارات المغنيسيوم.</p><p dir="RTL" style="text-align:justify">غلاف الكبسولة 200 ملغم يحتوي على:</p><p dir="RTL" style="text-align:justify">جيلاتين ، ثاني اكسيد التيتانيوم (إي 171).</p><p style="text-align:justify">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كبسولات 200 ملغم هي كبسولات صلبة ذات غلاف ابيض وجسم أبيض.</p><p dir="RTL">كبسولات 200 ملغم متوفرة في عبوات شرائط يحتوي كل منها على20 &nbsp;كبسولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق:</strong></p><p dir="RTL">شركة أجا للصناعات الدوائية المحدودة</p><p dir="RTL">حائل 55414، المملكة العربية السعودية</p><p dir="RTL">هاتف: 00966112687900</p><p dir="RTL">فاكس: 00966112687911</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">اتلانتيك فارما، بروديوسوز فارماسيتيكاس، اس ايه</p><p dir="RTL">ري ودا تابادا جراندي، رقم2؛ ابرونهيرا، 089-2710 سنترا، البرتغال.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 01/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CEBO 200 mg capsules, hard.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 200 mg celecoxib. Excipient(s) with known effect:
CEBO capsules contain lactose (each capsule, respectively, contains 74.9 mg or 149.8 mg lactose monohydrate; see section 4.4).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsule, hard.
CEBO 200 mg capsules, are hard capsules with white cap and white body.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.</p><p style="text-align:justify">The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient&#39;s overall risks (see sections 4.3, 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">As the cardiovascular risks of celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re- evaluated periodically, especially in patients with osteoarthritis (4.3, 4.4, 4.8 and 5.1).</p><p style="text-align:justify"><em>Osteoarthritis</em><strong>: </strong>The usual recommended daily dose is 200 mg taken once daily or in two divided doses. In some patients, with insufficient relief from symptoms, an increased dose of 200 mg twice daily may increase efficacy. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p style="text-align:justify"><em>Rheumatoid arthritis: </em>The initial recommended daily dose is 200 mg taken in two divided doses. The dose may, if needed, later be increased to 200 mg twice daily. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p style="text-align:justify"><em>Ankylosing Spondylitis: </em>The recommended daily dose is 200 mg taken once daily or in two divided doses. In a few patients, with insufficient relief from symptoms, an increased dose of 400 mg once daily or in two divided doses may increase efficacy. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p style="text-align:justify">The maximum recommended daily dose is 400 mg for all indications. CEBO may be taken with or without food.</p><p style="text-align:justify"><em>Elderly</em>: (&gt;65 years) As in younger adults, 200 mg per day should be used initially. The dose may, if needed, later be increased to 200 mg twice daily. Particular caution should be exercised in elderly with a body weight less than 50 kg. (See 4.4 and 5.2).</p><p style="text-align:justify"><em>Hepatic impairment: </em>Treatment should be initiated at half the recommended dose in patients with established moderate liver impairment with a serum albumin of 25-35 g/l. Experience in such patients is limited to cirrhotic patients (See 4.3, 4.4 and 5.2).</p><p style="text-align:justify"><em>Renal impairment: </em>Experience with celecoxib in patients with mild or moderate renal impairment is limited, therefore such patients should be treated with caution. (See 4.3, 4.4 and 5.2).</p><p style="text-align:justify"><em>Children: </em>Celecoxib is not indicated for use in children.</p><p style="text-align:justify"><em>CYP2C9 Poor Metabolizers: </em>Patients who are known, or suspected to be CYP2C9 poor metabolizers based on genotyping or previous history/experience with other CYP2C9 substrates should be administered celecoxib with caution as the risk of dose- dependent adverse effects is increased. Consider reducing the dose to half the lowest recommended dose. (See section 5.2)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1).
Known hypersensitivity to sulphonamides.
Active peptic ulceration or gastrointestinal (GI) bleeding.
Patients who have experienced asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.
In pregnancy and in women of childbearing potential unless using an effective method of contraception (See section 4.5). Celecoxib has been shown to cause malformations in the two animal species studied (See sections 4.6 and 5.3). The potential for human risk in pregnancy is unknown, but cannot be excluded.
Breast feeding (See sections 4.6 and 5.3).
Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score 10). Patients with estimated creatinine clearance <30 ml/min.
Inflammatory bowel disease. Congestive heart failure (NYHA II-IV).
Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>&ldquo;</strong><strong>WARNING:RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS&rdquo;</strong></p><p style="text-align:justify">Cardiovascular Thrombotic Events</p><p style="text-align:justify">Nonsteroidal anti-inflammatory drugs(NSAIDs)cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use.</p><p style="text-align:justify">Celecoxib capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</p><p style="text-align:justify">Gastrointestinal Bleeding, Ulceration, and Perforation</p><p style="text-align:justify">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious (GI) events.&rdquo;</p><p style="text-align:justify">Upper gastrointestinal complications [perforations, ulcers or bleedings (PUBs)], some of them resulting in fatal outcome, have occurred in patients treated with celecoxib.</p><p style="text-align:justify">Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other</p><p style="text-align:justify">NSAID or acetylsalicylic acid concomitantly or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.</p><p style="text-align:justify">There is further increase in the risk of gastrointestinal adverse effects for celecoxib (gastrointestinal ulceration or other gastrointestinal complications), when celecoxib is taken concomitantly with acetylsalicylic acid (even at low doses).</p><p style="text-align:justify">A significant difference in GI safety between selective COX-2 inhibitors + acetylsalicylic acid <em>vs</em>. NSAIDs + acetylsalicylic acid has not been demonstrated in long-term clinical trials (see section 5.1).</p><p style="text-align:justify">The concomitant use of celecoxib and a non- acetylsalycilic acid NSAID should be avoided.</p><p style="text-align:justify">Increased number of serious cardiovascular events, mainly myocardial infarction, has been found in a long-term placebo-controlled study in subjects with sporadic adenomatous polyps treated with celecoxib at doses of 200 mg twice daily and 400 mg twice daily compared to placebo (see section 5.1).</p><p style="text-align:justify">As the cardiovascular risks of celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re- evaluated periodically, especially in patients with osteoarthritis (see sections 4.2, 4.3, 4.8 and 5.1).</p><p style="text-align:justify">Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with celecoxib after careful consideration (see section 5.1).</p><p style="text-align:justify">COX-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effects. Therefore, antiplatelet therapies should not be discontinued (see section 5.1).</p><p style="text-align:justify">As with other drugs known to inhibit prostaglandin synthesis fluid retention and oedema have been observed in patients taking celecoxib. Therefore, celecoxib should be used with caution in patients with history of cardiac failure, left ventricular dysfunction or hypertension, and in patients with pre-existing oedema from any other reason, since prostaglandin inhibition may result in deterioration of renal function and fluid retention. Caution is also required in patients taking diuretic treatment or otherwise at risk of hypovolaemia.</p><p style="text-align:justify">As with all NSAIDS, celecoxib can lead to the onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of cardiovascular events. Therefore, blood pressure should be monitored closely during the initiation of therapy with celecoxib and throughout the course of therapy.</p><p style="text-align:justify">Compromised renal or hepatic function and especially cardiac dysfunction are more likely in the elderly and therefore medically appropriate supervision should be maintained.</p><p style="text-align:justify">NSAIDs, including celecoxib, may cause renal toxicity. Clinical trials with celecoxib have shown renal effects similar to those observed with comparator NSAIDs. Patients at greatest risk for renal toxicity are those with impaired renal function, heart failure, liver dysfunction, and the elderly. Such patients should be carefully monitored while receiving treatment with celecoxib.</p><p style="text-align:justify">Some cases of severe hepatic reactions, including fulminant hepatitis (some with fatal outcome), liver necrosis and, hepatic failure (some with fatal outcome or requiring liver transplant), have been reported with celecoxib. Among the cases that reported time to onset, most of the severe adverse hepatic events developed within one month after initiation of celecoxib treatment (see section 4.8).</p><p style="text-align:justify">If during treatment, patients deteriorate in any of the organ system functions described above, appropriate measures should be taken and discontinuation of celecoxib therapy should be considered.</p><p style="text-align:justify">Celecoxib inhibits CYP2D6. Although it is not a strong inhibitor of this enzyme, a dose reduction may be necessary for individually dose-titrated drugs that are metabolised by CYP2D6 (See section 4.5).</p><p style="text-align:justify">Patients known to be CYP2C9 poor metabolisers should be treated with caution (see section 5.2.).</p><p style="text-align:justify">Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens- Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of celecoxib (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Serious hypersensitivity reactions (anaphylaxis and angioedema) have been reported in patients receiving celecoxib (see section 4.8). Patients with a history of sulphonamide allergy or any drug allergy may be at greater risk of serious skin reactions or hypersensitivity reactions (see section 4.3). Celecoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p style="text-align:justify">Celecoxib may mask fever and other signs of inflammation.</p><p style="text-align:justify">In patients on concurrent therapy with warfarin, serious bleeding events have occurred. Caution should be exercised when combining celecoxib with warfarin and other oral anticoagulants (See 4.5).</p><p style="text-align:justify">CEBO 200 mg capsules contain lactose monohydrate (74.9 mg and 149.8 mg, respectively). Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Pharmacodynamic interactions</em></p><p style="text-align:justify">Anticoagulant activity should be monitored particularly in the first few days after initiating or changing the dose of celecoxib in patients receiving warfarin or other</p><p style="text-align:justify">anticoagulants since these patients have an increased risk of bleeding complications. Therefore, patients receiving oral anticoagulants should be closely monitored for their prothrombin time INR, particularly in the first few days when therapy with celecoxib is initiated or the dose of celecoxib is changed (see 4.4). Bleeding events in association with increases in prothrombin time have been reported, predominantly in the elderly, in patients receiving celecoxib concurrently with warfarin, some of them fatal.</p><p style="text-align:justify">NSAIDs may reduce the effect of diuretics and antihypertensive medicinal products. As for NSAIDs, the risk of acute renal insufficiency, which is usually reversible, may be increased in some patients with compromised renal function (e.g. dehydrated patients or elderly patients) when ACE inhibitors or angiotensin II receptor antagonists are combined with NSAIDs, including celecoxib. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter.</p><p style="text-align:justify">In a 28-day clinical study in patients with lisinopril-controlled Stage I and II hypertension, administration of celecoxib 200 mg twice daily resulted in no clinically significant increases, when compared to placebo treatment, in mean daily systolic or diastolic blood pressure as determined using 24-hour ambulatory blood pressure monitoring. Among patients treated with celecoxib 200 mg twice daily, 48% were considered unresponsive to lisinopril at the final clinic visit (defined as either cuff diastolic blood pressure &gt;90 mmHg or cuff diastolic blood pressure increased &gt;10% compared to baseline), compared to 27% of patients treated with placebo; this difference was statistically significant.</p><p style="text-align:justify">Coadministration of NSAIDs and ciclosporin or tacrolimus have been suggested to increase the nephrotoxic effect of ciclosporin and tacrolimus. Renal function should be monitored when celecoxib and any of these drugs are combined.</p><p style="text-align:justify">Celecoxib can be used with low-dose acetylsalicylic acid but is not a substitute for acetylsalicylic acid for cardiovascular prophylaxis. In the submitted studies, as with other NSAIDs, an increased risk of gastrointestinal ulceration or other gastrointestinal complications compared to use of celecoxib alone was shown for concomitant administration of low-dose acetylsalicylic acid (see section 5.1).</p><p style="text-align:justify"><em>Pharmacokinetic interactions Effects of celecoxib on other drugs</em></p><p style="text-align:justify">Celecoxib is an inhibitor of CYP2D6. During celecoxib treatment, the plasma concentrations of the CYP2D6 substrate dextromethorphan were increased by 136%. The plasma concentrations of drugs that are substrates of this enzyme may be increased when celecoxib is used concomitantly. Examples of drugs which are metabolised by CYP2D6 are antidepressants (tricyclics and SSRIs), neuroleptics, anti- arrhythmic drugs, etc. The dose of individually dose-titrated CYP2D6 substrates may need to be reduced when treatment with celecoxib is initiated or increased if treatment with celecoxib is terminated.</p><p style="text-align:justify"><em>In vitro </em>studies have shown some potential for celecoxib to inhibit CYP2C19 catalysed metabolism. The clinical significance of this <em>in vitro </em>finding is unknown. Examples of drugs which are metabolised by CYP2C19 are diazepam, citalopram and imipramine.</p><p style="text-align:justify">In an interaction study, celecoxib had no clinically relevant effects on the pharmacokinetics of oral contraceptives (1 mg norethistherone /35 microg ethinylestradiol).</p><p style="text-align:justify">Celecoxib does not affect the pharmacokinetics of tolbutamide (CYP2C9 substrate), or glibenclamide to a clinically relevant extent.</p><p style="text-align:justify">In patients with rheumatoid arthritis celecoxib had no statistically significant effect on the pharmacokinetics (plasma or renal clearance) of methotrexate (in rheumatologic doses). However, adequate monitoring for methotrexate-related toxicity should be considered when combining these two drugs.</p><p style="text-align:justify">In healthy subjects, co-administration of celecoxib 200 mg twice daily with 450 mg twice daily of lithium resulted in a mean increase in Cmax of 16% and in AUC of 18% of lithium. Therefore, patients on lithium treatment should be closely monitored when celecoxib is introduced or withdrawn.</p><p style="text-align:justify"><em>Effects of other drugs on celecoxib</em></p><p style="text-align:justify">In individuals who are CYP2C9 poor metabolisers and demonstrate increased systemic exposure to celecoxib, concomitant treatment with CYP2C9 inhibitors could result in further increases in celecoxib exposure. Such combinations should be avoided in known CYP2C9 poor metabolisers (see sections 4.2 and 5.2).</p><p style="text-align:justify">Since celecoxib is predominantly metabolised by CYP2C9 it should be used at half the recommended dose in patients receiving fluconazole. Concomitant use of 200 mg single dose of celecoxib and 200 mg once daily of fluconazole, a potent CYP2C9 inhibitor, resulted in a mean increase in celecoxib Cmax of 60% and in AUC of 130%. Concomitant use of inducers of CYP2C9 such as rifampicin, carbamazepine and barbiturates may reduce plasma concentrations of celecoxib.</p><p style="text-align:justify">Ketoconazole or antacids have not been observed to affect the pharmacokinetics of celecoxib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">No clinical data on exposed pregnancies are available for celecoxib. Studies in animals (rats and rabbits) have shown reproductive toxicity, including malformations (see 4.3 and 5.3). The potential for human risk in pregnancy is unknown, but cannot be excluded. Celecoxib, as with other drugs inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester. Celecoxib is contraindicated in pregnancy and in women who can become pregnant (see 4.3 and 4.4). If a woman becomes pregnant during treatment, celecoxib should be discontinued.</p><p style="text-align:justify">Celecoxib is excreted in the milk of lactating rats at concentrations similar to those in plasma. Administration of celecoxib to a limited number of lactating women has shown a very low transfer of celecoxib into breast milk. Women who take celecoxib should not breastfeed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Patients who experience dizziness, vertigo or somnolence while taking celecoxib should refrain from driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Adverse reactions are listed by system organ class and ranked by frequency in</p><p style="text-align:justify"><strong>Table 1</strong>, reflecting data from the following sources:</p><p style="text-align:justify">&middot;&nbsp;&nbsp; Adverse reactions reported in osteoarthritis patients and rheumatoid arthritis patients at incidence rates greater than 0.01% and greater than those reported for placebo during 12 placebo- and/or active-controlled clinical trials of duration up to 12 weeks at celecoxib daily doses from 100 mg up to 800 mg. In additional studies using non-selective NSAID comparators, approximately 7400 arthritis patients have been treated with celecoxib at daily doses up to 800 mg, including approximately 2300 patients treated for 1 year or longer. The adverse reactions observed with celecoxib in these additional studies were consistent with those for osteoarthritis and rheumatoid arthritis patients listed in <strong>Table 1</strong>.</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions reported at incidence rates greater than placebo for subjects treated with celecoxib 400 mg daily in long-term polyp prevention trials of duration up to 3 years (the APC and PreSAP trials; see Section 5.1, Pharmacodynamic properties: Cardiovascular Safety &ndash; Long-Term Studies Involving Patients With Sporadic Adenomatous Polyps).</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse drug reactions from post-marketing surveillance as spontaneously reported during a period in which an estimated &gt;70 million patients were treated with celecoxib (various doses, durations, and indications). Because not all adverse drug reactions are reported to the MAH and included in the safety database, the frequencies of these reactions cannot be reliably determined.</p><p style="text-align:justify"><strong>Table 1. Adverse Drug Reactions&nbsp; in&nbsp; Celecoxib&nbsp; Clinical&nbsp; Trials&nbsp; and&nbsp; Surveillance Experience (MedDRA Preferred Terms)<sup>1,2</sup></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td rowspan="1" colspan="5" style="vertical-align:top"><strong>Adverse Drug Reaction Frequency</strong></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>System class organ</strong></p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Very Common</strong></p><p style="text-align:justify">(&ge;1/10)</p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Common</strong></p><p style="text-align:justify">(&ge;1/100 to &lt;1/10)</p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Uncommon</strong></p><p style="text-align:justify">(&ge;1/1000 to</p><p style="text-align:justify">&lt;1/100)</p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Rare</strong></p><p style="text-align:justify">(&ge;1/10,000 to &lt;1/1000)</p></td><td style="vertical-align:top"><strong>Not Known (Cannot&nbsp; be&nbsp;estimated from the available data)</strong>(Post-marketing&nbsp;experience)<sup>3</sup></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Sinusitis, upper respiratory tract infection, urinary</p><p style="text-align:justify">tract infection</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Blood and lymphatic</strong></p><p style="text-align:justify"><strong>system disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Anemia</p></td><td style="vertical-align:top"><p style="text-align:justify">Leucopenia, thrombocytopenia</p></td><td style="vertical-align:top"><p style="text-align:justify">Pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Allergy aggravated</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Serious allergic reactions, anaphylactic</p><p style="text-align:justify">shock, anaphylaxis</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify">Hyperkaelemia</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Insomnia</p></td><td style="vertical-align:top"><p style="text-align:justify">Anxiety, depression,</p><p style="text-align:justify">tiredness</p></td><td style="vertical-align:top"><p style="text-align:justify">Confusion</p></td><td style="vertical-align:top"><p style="text-align:justify">Hallucinations</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Dizziness, hypertonia</p></td><td style="vertical-align:top"><p style="text-align:justify">Paraesthesia, somnolence, cerebral infarction<sup>1</sup></p></td><td style="vertical-align:top"><p style="text-align:justify">Ataxia, taste alteration</p></td><td style="vertical-align:top"><p style="text-align:justify">Headache, aggravated epilepsy, meningitis aseptic, ageusia, anosmia, fatal</p><p style="text-align:justify">intracranial haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Blurred vision</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Conjunctivitis, ocular haemorrhage, retinal artery or</p><p style="text-align:justify">vein occlusion</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Ear and labyrinth</strong></p><p style="text-align:justify"><strong>disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Tinnitus, hypoacusis<sup>1</sup></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Myocardial infarction<sup>1</sup></p></td><td style="vertical-align:top"><p style="text-align:justify">Heart failure,</p><p style="text-align:justify">palpitations, tachycardia</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Arrhythmia</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">Hyper- tension<sup>1</sup></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Hypertension aggravated</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Flushing, vasculitis, pulmonary</p><p style="text-align:justify">embolism</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Respiratory, thoracic, and mediastinal</strong></p><p style="text-align:justify"><strong>disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Pharyngitis, rhinitis, cough, dyspnoea<sup>1</sup></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Bronchospasm</p></td></tr><tr><td style="vertical-align:top"><strong>Gastrointestinal disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Abdominal pain, diarrhoea, dyspepsia, flatulence, vomiting<sup>1</sup>dysphagia<sup>1</sup></td><td style="vertical-align:top">Constipation, eructation, gastritis, stomatitis, aggravation of gastrointestinal inflammation</td><td style="vertical-align:top"><p style="text-align:justify">Duodenal, gastric, oesophageal, intestinal, and colonic ulceration; intestinal perforation; oesophagitis,</p><p style="text-align:justify">melaena; pancreatitis</p></td><td style="vertical-align:top">Nausea, gastrointestinal haemorrhage, colitis/colitis aggravated</td></tr><tr><td style="vertical-align:top"><strong>Hepatobiliary disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Abnormal hepatic function, increased SGOT and SGPT</td><td style="vertical-align:top">Elevation of hepatic enzymes</td><td style="vertical-align:top"><p style="text-align:justify">Hepatic failure (sometimes fatal or requiring liver transplant), fulminant hepatitis (some with fatal outcome), liver necrosis, hepatitis jaundice</p></td></tr><tr><td style="vertical-align:top"><strong>Skin and subcutaneous tissue disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Rash, pruritus</td><td style="vertical-align:top">Urticaria</td><td style="vertical-align:top">Alopecia, photosensitivity</td><td style="vertical-align:top"><p style="text-align:justify">Ecchymosis, bullous eruption, exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, acute generalized exanthematous pustulosis</p></td></tr><tr><td style="vertical-align:top"><strong>Musculoskeletal and connective tissue disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Leg cramps</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Arthralgia, myositis</td></tr><tr><td style="vertical-align:top"><strong>Renal and urinary disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Increased creatinine, BUN increased</td><td style="vertical-align:top"><p style="text-align:justify">Acute renal failure, interstitial nephritis, hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><strong>Reproductive system and breast disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Menstrual disorder NOS</td></tr><tr><td style="vertical-align:top"><strong>General disorders and administrative site conditions</strong></td><td style="vertical-align:top">Flu-like symptoms, peripheral oedema/ fluid retention</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Chest pain</td></tr></tbody></table><p style="text-align:justify"><sup>1</sup> Adverse drug reactions that occurred in polyp prevention trials, representing subjects treated with celecoxib 400 mg daily in 2 clinical trials of duration up to 3 years (the APC and PreSAP trials). The adverse drug reactions listed above for the polyp prevention trials are only those that have been previously recognized in the post-marketing surveillance experience, or have occurred more frequently than in the arthritis trials.</p><p style="text-align:justify"><sup>2</sup> Furthermore, the following <em>previously unknown </em>adverse reactions occurred in polyp prevention&nbsp; trials, representing subjects treated&nbsp; with celecoxib 400 mg daily in 2 clinical&nbsp; trials of duration up to&nbsp;&nbsp; 3 years (the APC and PreSAP trials):&nbsp;<strong>Common: </strong>angina pectoris, irritable bowel syndrome, nephrolithiasis, blood creatinine increased, benign prostatic hyperplasia, weight increased. <strong>Uncommon: </strong>helicobacter infection, herpes zoster, erysipelas, bronchopneumonia, labyrinthitis, gingival infection, lipoma, vitreous floaters, conjunctival haemorrhage, deep vein thrombosis, dysphonia, haemorrhoidal haemorrhage, frequent bowel movements, mouth ulceration, allergic dermatitis, ganglion, nocturia, vaginal haemorrhage, breast tenderness, lower limb fracture, blood sodium increased.</p><p style="text-align:justify"><sup>3</sup> Adverse drug reactions spontaneously reported to the safety surveillance database over a period in which an estimated &gt;70 million patients were treated with celecoxib (various doses, durations, and indications). As a result, the frequencies of these adverse drug reactions cannot be reliably determined. Adverse drug reactions listed for the post-marketing population are only those that are not already listed for the arthritis trials or the polyp prevention trials.</p><p style="text-align:justify">In final data (adjudicated) from the APC and PreSAP trials in patients treated with celecoxib 400 mg daily for up to 3 years (pooled data from both trials; see Section 5.1 for results from individual trials), the excess rate over placebo for myocardial infarction was 7.6 events per 1000 patients (uncommon) and there was no excess rate for stroke (types not differentiated) over placebo.</p><p>To report any side effect(s):</p><ul><li><strong>Saudi Arabia:</strong><ul><li>The National Pharmacovigilance Centre (NPC)<ul><li>Fax: +966-11-205-7662</li><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa&nbsp;</li></ul></li></ul></li><li><strong>Other GCC States:</strong><br />Please contact the relevant competent authority.</li></ul><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">There is no clinical experience of overdose. Single doses up to 1200 mg and multiple doses up to 1200 mg twice daily have been administered to healthy subjects for nine days without clinically significant adverse effects. In the event of suspected overdose, appropriate supportive medical care should be provided e.g. by eliminating the gastric contents, clinical supervision and, if necessary, the institution of symptomatic treatment. Dialysis is unlikely to be an efficient method of drug removal due to high protein binding.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non- steroids, Coxibs.</p><p style="text-align:justify">ATC code: M01AH01.</p><p style="text-align:justify">Celecoxib is an oral, selective, cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range (200-400 mg daily). No statistically significant inhibition of COX- 1 (assessed as <em>ex vivo </em>inhibition of thromboxane B<sub>2</sub> [TxB<sub>2</sub>] formation) was observed in this dose range in healthy volunteers.</p><p style="text-align:justify">Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX- 1 and COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function). It may also play a role in ulcer healing. COX-2 has been identified in tissue around gastric ulcers in man but its relevance to ulcer healing has not been established.</p><p style="text-align:justify">The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and COX-2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions. COX-2 selective inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.</p><p style="text-align:justify">Celecoxib is a diaryl-substituted pyrazole, chemically similar to other non-arylamine sulfonamides (e.g. thiazides, furosemide) but differs from arylamine sulfonamides (e.g. sulfamethoxizole and other sulfonamide antibiotics).</p><p style="text-align:justify">A dose dependent effect on TxB<sub>2</sub> formation has been observed after high doses of celecoxib. However, in healthy subjects, in small multiple dose studies with 600 mg BID (three times the highest recommended dose) celecoxib had no effect on platelet aggregation and bleeding time compared to placebo.</p><p style="text-align:justify">Several clinical studies have been performed confirming efficacy and safety in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Celecoxib was evaluated for the treatment of the inflammation and pain of OA of the knee and hip in approximately 4200 patients in placebo and active controlled trials of up to 12 weeks duration. It was also evaluated for treatment of the inflammation and pain of RA in approximately 2100 patients in placebo and active controlled trials of up to 24 weeks duration. Celecoxib at daily doses of 200 mg &ndash; 400 mg provided pain relief within 24 hours of dosing. Celecoxib was evaluated for the symptomatic treatment of ankylosing spondylitis in 896 patients in placebo and active controlled trials of up to 12 weeks duration. Celecoxib at doses of 100 mg BID, 200 mg QD, 200 mg BID and 400 mg QD in these studies demonstrated significant improvement in pain, global disease activity and function in ankylosing spondylitis.</p><p style="text-align:justify">Five randomised double-blind controlled studies have been conducted including scheduled upper gastrointestinal endoscopy in approximately 4500 patients free from initial ulceration (celecoxib doses from 50 mg-400 mg BID). In twelve week endoscopy studies celecoxib (100-800 mg per day) was associated with a significantly lower risk of gastroduodenal ulcers compared with naproxen (1000 mg per day) and ibuprofen (2400 mg per day). The data were inconsistent in comparison with diclofenac (150 mg per day). In two of the 12-week studies the percentage of patients with endoscopic gastroduodenal ulceration were not significantly different between placebo and celecoxib 200 mg BID and 400 mg BID.</p><p style="text-align:justify">In a prospective long-term safety outcome study (6 to 15 month duration, CLASS study), 5,800 OA and 2,200 RA patients received celecoxib 400 mg BID (4-fold and 2-fold the recommended OA and RA doses, respectively), ibuprofen 800 mg TID or diclofenac 75 mg BID (both at therapeutic doses). Twenty-two percent of enrolled patients took concomitant low-dose acetylsalicylic acid (&pound;325 mg/day), primarily for cardiovascular prophylaxis. For the primary endpoint complicated ulcers (defined as gastrointestinal bleeding, perforation or obstruction) celecoxib was not significantly different than either ibuprofen or diclofenac individually. Also for the combined NSAID group there was no statically significant difference for complicated ulcers (relative risk 0,77, 95 % CI 0.41-1.46, based on entire study duration). For the combined endpoint, complicated and symptomatic ulcers, the incidence was significantly lower in the celecoxib group compared to the NSAID group, relative risk 0.66, 95% CI 0.45-0.97 but not between celecoxib and diclofenac. Those patients on celecoxib and concomitant low-dose acetylsalicylic acid experienced 4 fold higher rates of complicated ulcers as compared to those on celecoxib alone. The incidence of clinically significant decreases in haemoglobin (&gt;2 g/dL), confirmed by repeat testing, was significantly lower in patients on celecoxib compared to the NSAID group, relative risk 0.29, 95% CI 0.17- 0.48. The significantly lower incidence of this event with celecoxib was maintained with or without acetylsalicylic acid use.</p><p style="text-align:justify">In a prospective randomised 24 week safety study in patients who were aged &ge; 60 years or had a history of gastroduodenal ulcers (users of ASA excluded), the percentages of patients with decreases in haemoglobin (&ge; 2 g/dl) and/or haematocrit (&ge; 10 %) of defined or presumed GI origin were lower in patients treated with celecoxib 200 mg twice daily (N = 2,238) compared to patients treated with diclofenac SR 75 mg twice daily plus omeprazole 20 mg once daily (N = 2,246) (0.2 % vs. 1.1 % for defined GI origin, p = 0.004; 0.4 % vs. 2.4 % for presumed GI origin, p = 0.0001). The rates of clinically manifest GI complications such as perforation, obstruction or haemorrhage were very low with no differences between the treatment groups (4-5 per group).</p><p style="text-align:justify">Cardiovascular Safety &ndash; Long-Term Studies Involving Subjects With Sporadic Adenomatous Polyps</p><p style="text-align:justify">Two studies involving subjects with sporadic adenomatous polyps were conducted with celecoxib i.e., the APC trial (Adenoma Prevention with Celecoxib) and the PreSAP trial (Prevention of Spontaneous Adenomatous Polyps). In theAPC trial, there was a dose-related increase in the composite endpoint of cardiovascular death, myocardial infarction, or stroke (adjudicated) with celecoxib compared to placebo over 3 years of treatment. The PreSAP trial did not demonstrate a statistically significant increased risk for the same composite endpoint.</p><p style="text-align:justify">In the APC trial, the relative risks compared to placebo for a composite endpoint (adjudicated) of cardiovascular death, myocardial infarction, or stroke were</p><p style="text-align:justify">3.4 (95% CI 1.4 - 8.5) with celecoxib 400 mg twice daily and 2.8 (95% CI 1.1 - 7.2) with celecoxib 200 mg twice daily. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects), respectively, compared to 0.9% (6/679 subjects) for placebo. The increases for both celecoxib dose groups versus placebo were mainly due to an increased incidence of myocardial infarction.</p><p style="text-align:justify">In the PreSAP trial, the relative risk compared to placebo for this same composite endpoint (adjudicated) was 1.2 (95% CI 0.6 - 2.4) with celecoxib 400 mg once daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 2.3% (21/933 subjects) and 1.9% (12/628 subjects), respectively. The incidence of myocardial infarction (adjudicated) was 1.0% with (9/933 subjects) with celecoxib 400 mg once daily and 0.6% (4/628 subjects) with placebo.</p><p style="text-align:justify">Data from a third long-term study, ADAPT (The Alzheimer&#39;s Disease Anti- inflammatory Prevention Trial), did not show a significantly increased cardiovascular risk with celecoxib 200mg BID compared to placebo. The relative risk compared to placebo for a similar composite endpoint (CV death, MI, stroke) was 1.14 (95% CI 0.61 - 2.12) with celecoxib 200 mg twice daily. The incidence of myocardial infarction was 1.1% (8/717 patients) with celecoxib 200 mg twice daily and 1.2% (13/1070 patients) with placebo.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Celecoxib is well absorbed reaching peak plasma concentrations after approximately 2-3 hours. Dosing with food (high fat meal) delays absorption by about 1 hour.</p><p style="text-align:justify">Celecoxib is mainly eliminated by metabolism. Less than 1% of the dose is excreted unchanged in urine. The inter-subject variability in the exposure of celecoxib is about 10-fold. Celecoxib exhibits dose- and time-independent pharmacokinetics in the therapeutic dose range. Plasma protein binding is about 97% at therapeutic plasma concentrations and the drug is not preferentially bound to erythrocytes. Elimination half-life is 8-12 hours. Steady state plasma concentrations are reached within 5 days of treatment. Pharmacological activity resides in the parent drug. The main metabolites found in the circulation have no detectable COX-1 or COX-2 activity.</p><p style="text-align:justify">Celecoxib metabolism is primarily mediated via cytochrome P450 2C9. Three metabolites, inactive as COX-1 or COX-2 inhibitors, have been identified in human plasma i.e., a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate.</p><p style="text-align:justify">Cytochrome P450 2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*3 polymorphism.</p><p style="text-align:justify">In a pharmacokinetic study of celecoxib 200 mg administered once daily in healthy volunteers, genotyped as either CYP2C9*1/*1, CYP2C9*1/*3, or CYP2C9*3/*3, the median Cmax and AUC 0-24 of celecoxib on day 7 were approximately 4-fold and 7- fold, respectively, in subjects genotyped as CYP2C9*3/*3 compared to other genotypes. In three separate single dose studies, involving a total of 5 subjects genotyped as CYP2C9*3/*3, single-dose AUC 0-24 increased by approximately 3- fold compared to normal metabolizers. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3-1.0% among different ethnic groups.</p><p style="text-align:justify">Patients who are known, or suspected to be CYP2C9 poor metabolizers based on previous history/experience with other CYP2C9 substrates should be administered celecoxib with caution (see Section 4.2).</p><p style="text-align:justify">No clinically significant differences were found in PK parameters of celecoxib between elderly African-Americans and Caucasians.</p><p style="text-align:justify">The plasma concentration of celecoxib is approximately 100% increased in elderly women (&gt;65 years).</p><p style="text-align:justify">Compared to subjects with normal hepatic function, patients with mild hepatic impairment had a mean increase in Cmax of 53% and in AUC of 26% of celecoxib. The corresponding values in patients with moderate hepatic impairment were 41% and 146% respectively. The metabolic capacity in patients with mild to moderate impairment was best correlated to their albumin values. Treatment should be initiated at half the recommended dose in patients with moderate liver impairment (with serum albumin 25-35g/L). Patients with severe hepatic impairment (serum albumin &lt;25 g/l) have not been studied and celecoxib is contraindicated in this patient group.</p><p style="text-align:justify">There is little experience of celecoxib in renal impairment. The pharmacokinetics of celecoxib has not been studied in patients with renal impairment but is unlikely to be markedly changed in these patients. Thus caution is advised when treating patients with renal impairment. Severe renal impairment is contraindicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Conventional embryo-fetal toxicity studies resulted in dose dependent occurrences of diaphragmatic hernia in rat fetuses and of cardiovascular malformations in rabbit fetuses at systemic exposures to free drug approximately 5X (rat) and 3X (rabbit) higher than those achieved at the maximum recommended daily human dose (400 mg). Diaphragmatic hernia was also seen in a peri-post natal toxicity study in rats, which included exposure during the organogenetic period. In the latter study, at the lowest systemic exposure where this anomaly occurred in a single animal, the estimated margin relative to the maximum recommended daily human dose was 3X.</p><p style="text-align:justify">In animals, exposure to celecoxib during early embryonic development resulted in pre-implantation and post-implantation losses. These effects are expected following inhibition of prostaglandin synthesis.</p><p style="text-align:justify">Celecoxib was excreted in rat milk. In a peri-post natal study in rats, pup toxicity was observed.</p><p style="text-align:justify">Based on conventional studies, genotoxicity or carcinogenicity, no special hazard for humans was observed, beyond those addressed in other sections of the SmPC. In a two-year toxicity study an increase in nonadrenal thrombosis was observed in male rat at high doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsules contain</u>:</p><p>Lactose monohydrate Croscarmellose sodium Povidone K30 Sodium laurilsulfate Magnesium stearate.</p><p><u>Capsules 200 mg shells contain</u>: Gelatin</p><p>Titanium dioxide (E171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CEBO 200 mg is packed in PVC and Aluminum blisters in 20 capsules packages.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA Pharmaceutical Industries Company, Ltd. 
Hail Industrial City MODON, Street No 32 
PO Box 6979, Hail 55414 
Kingdom of Saudi Arabia
Tel: +966 11 268 7900
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>